Author name: DrugPatentWatch

To identify Key Starting Materials (KSMs) for Active Pharmaceutical Ingredients (APIs), pharmaceutical companies and regulatory bodies follow a systematic approach […]
Source

The generic drug market has been significantly impacted by the COVID-19 pandemic, with both challenges and opportunities arising from the […]
Source

In the high-stakes world of pharmaceuticals, generic drugs have become the unsung heroes of healthcare accessibility. These cost-effective alternatives to […]
Source

In the high-stakes world of pharmaceutical innovation, drafting detailed drug patent claims is a critical process that can make or […]
Source

As patents expire on blockbuster biologic drugs, manufacturers are increasingly employing a controversial tactic known as “product hopping” to maintain […]
Source

Enantiomer Switching: A Pharmaceutical Strategy to Extend Drug Patents Enantiomer switching, also known as chiral switching, is a strategy employed […]
Source

In the rapidly evolving landscape of biosimilars, intellectual property (IP) strategy is paramount. Biosimilar manufacturers face unique challenges, including navigating […]
Source

Introduction The Patent Trial and Appeal Board (PTAB) is a crucial component of the United States Patent and Trademark Office […]
Source

Transitioning to a new Contract Development and Manufacturing Organization (CDMO) can be a complex and challenging process. However, by following […]
Source

The High Stakes of Pharmaceutical Patent Litigation In the fiercely competitive pharmaceutical industry, patent disputes can make or break a […]
Source